Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review
Chenxi Liu, Ying-Ying Jin, Xiqiong Han, Hua Huang, Shengfang Bao, Xuemei Xu, Liping Wang, Yanliang Jin Department of Rheumatology and Immunology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People’s Republic of ChinaCorrespondence: Yanliang...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/baricitinib-successfully-treated-a-teenager-with-refractory-livedoid-v-peer-reviewed-fulltext-article-JIR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832570207208472576 |
|---|---|
| author | Liu C Jin YY Han X Huang H Bao S Xu X Wang L Jin Y |
| author_facet | Liu C Jin YY Han X Huang H Bao S Xu X Wang L Jin Y |
| author_sort | Liu C |
| collection | DOAJ |
| description | Chenxi Liu, Ying-Ying Jin, Xiqiong Han, Hua Huang, Shengfang Bao, Xuemei Xu, Liping Wang, Yanliang Jin Department of Rheumatology and Immunology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People’s Republic of ChinaCorrespondence: Yanliang Jin, Email jinyanliang@scmc.com.cnBackground: The pathogenesis is of livedoid vasculopathy (LV)—a rare, chronic, and recurrent cutaneous vascular obstructive disease—is not fully understood. Conventional anticoagulant therapy sometimes exhibits limited efficacy, and although JAK inhibitors have demonstrated some efficacy in the treatment of refractory LV, the evidence remains insufficient.Case Presentation: This study reports a case of a 14-year-old girl who were failed to maintain remission following treatment with oral rivaroxaban combined with external use of heparin sodium cream. However, the symptoms improved significantly 2 weeks after treatment with baricitinib, and remission was maintained during its gradual reduction.Conclusion: Successful treatment of this refractory patient with baricitinib provides another evidence for the potential therapeutic effect of JAK1/JAK2 inhibitors in LV, and also offers a reference for the dosage tapering regime of baricitinib in LV.Keywords: livedoid vasculopathy, refractory, baricitinib |
| format | Article |
| id | doaj-art-5db7785177254ebea3cd71bea5017842 |
| institution | Kabale University |
| issn | 1178-7031 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj-art-5db7785177254ebea3cd71bea50178422025-02-02T15:59:40ZengDove Medical PressJournal of Inflammation Research1178-70312025-02-01Volume 181471147799812Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature ReviewLiu CJin YYHan XHuang HBao SXu XWang LJin YChenxi Liu, Ying-Ying Jin, Xiqiong Han, Hua Huang, Shengfang Bao, Xuemei Xu, Liping Wang, Yanliang Jin Department of Rheumatology and Immunology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People’s Republic of ChinaCorrespondence: Yanliang Jin, Email jinyanliang@scmc.com.cnBackground: The pathogenesis is of livedoid vasculopathy (LV)—a rare, chronic, and recurrent cutaneous vascular obstructive disease—is not fully understood. Conventional anticoagulant therapy sometimes exhibits limited efficacy, and although JAK inhibitors have demonstrated some efficacy in the treatment of refractory LV, the evidence remains insufficient.Case Presentation: This study reports a case of a 14-year-old girl who were failed to maintain remission following treatment with oral rivaroxaban combined with external use of heparin sodium cream. However, the symptoms improved significantly 2 weeks after treatment with baricitinib, and remission was maintained during its gradual reduction.Conclusion: Successful treatment of this refractory patient with baricitinib provides another evidence for the potential therapeutic effect of JAK1/JAK2 inhibitors in LV, and also offers a reference for the dosage tapering regime of baricitinib in LV.Keywords: livedoid vasculopathy, refractory, baricitinibhttps://www.dovepress.com/baricitinib-successfully-treated-a-teenager-with-refractory-livedoid-v-peer-reviewed-fulltext-article-JIRlivedoid vasculopathyrefractorybaricitinib |
| spellingShingle | Liu C Jin YY Han X Huang H Bao S Xu X Wang L Jin Y Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review Journal of Inflammation Research livedoid vasculopathy refractory baricitinib |
| title | Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review |
| title_full | Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review |
| title_fullStr | Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review |
| title_full_unstemmed | Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review |
| title_short | Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review |
| title_sort | baricitinib successfully treated a teenager with refractory livedoid vasculopathy a case report and literature review |
| topic | livedoid vasculopathy refractory baricitinib |
| url | https://www.dovepress.com/baricitinib-successfully-treated-a-teenager-with-refractory-livedoid-v-peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT liuc baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview AT jinyy baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview AT hanx baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview AT huangh baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview AT baos baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview AT xux baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview AT wangl baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview AT jiny baricitinibsuccessfullytreatedateenagerwithrefractorylivedoidvasculopathyacasereportandliteraturereview |